Skip to main content

Ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Intervista a Binod Dhakal By 5 Giugno 2023No Comments

Why are the data from CARTITUDE-4 so important? Is cilta-cel a potential new standard of care in relapsed/refractory multiple myeloma? We asked Binod Dhakal, Associate Professor Medical College of Wisconsin Cancer Center – Froedtert Hospital, Milwaukee), during ASCO 2023 in Chicago.